Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CAR-T Cells for the Treatment of Multiple Myeloma
NCT06006741Phase 1Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Jul 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MM-specific universal CAR T cells in multiple myeloma (MM), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Percentage of patients with treatment related adverse effect at 6 months. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
MM-specific universal CAR T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06006741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006741.